158 related articles for article (PubMed ID: 12624802)
1. [5-HT3-receptor-antagonists in therapy of rheumatic diseases].
Müller W; Stratz T
Z Rheumatol; 2003 Feb; 62(1):39-41. PubMed ID: 12624802
[No Abstract] [Full Text] [Related]
2. The use of 5-HT3 receptor antagonists in various rheumatic diseases--a clue to the mechanism of action of these agents in fibromyalgia?
Stratz T; Müller W
Scand J Rheumatol Suppl; 2000; 113():66-71. PubMed ID: 11028836
[TBL] [Abstract][Full Text] [Related]
3. [Pilot study with 5-HT3 antagonists. Good outcome in fibromyalgia pain].
Stratz T; Müller W
MMW Fortschr Med; 2002 Mar; 144(11):49. PubMed ID: 12066514
[No Abstract] [Full Text] [Related]
4. [5-HT3 receptor antagonists as a new therapeutic principle in rheumatology?].
Pongratz D
Z Rheumatol; 2001 Feb; 60(1):47-8. PubMed ID: 11263014
[No Abstract] [Full Text] [Related]
5. [Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors].
Stratz T; Schochat T; Hrycaj P; Lacki J; Mennet P; Färber L; Schweiger C; Müller W
Z Rheumatol; 1994; 53(6):335-8. PubMed ID: 7871905
[TBL] [Abstract][Full Text] [Related]
6. [5-HT3 receptor antagonist als analgetics in rheumatic diseases].
Müller W; Fiebich BL; Stratz T
Z Rheumatol; 2006 Oct; 65(6):546, 548-52. PubMed ID: 16450149
[TBL] [Abstract][Full Text] [Related]
7. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.
Papadopoulos IA; Georgiou PE; Katsimbri PP; Drosos AA
Clin Rheumatol; 2000; 19(1):6-8. PubMed ID: 10752491
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
[TBL] [Abstract][Full Text] [Related]
9. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
Stratz T; Müller W
Scand J Rheumatol Suppl; 2000; 113():63-5. PubMed ID: 11028835
[TBL] [Abstract][Full Text] [Related]
10. 5-HT3 receptor antagonists: a new therapeutic approach in rheumatology? Proceedings of a symposium. Frankfurt, Germany, February 12-13, 2004.
Scand J Rheumatol Suppl; 2004; 119():1-80. PubMed ID: 15584135
[No Abstract] [Full Text] [Related]
11. Current experience with 5-HT3 receptor antagonists in fibromyalgia.
Späth M
Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920
[TBL] [Abstract][Full Text] [Related]
12. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia.
Höcherl K; Färber L; Ladenburger S; Vosshage D; Stratz T; Müller W; Grobecker H
Scand J Rheumatol Suppl; 2000; 113():46-8. PubMed ID: 11028831
[TBL] [Abstract][Full Text] [Related]
13. [Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron].
Stratz T; Müller W
Schmerz; 2003 Jun; 17(3):200-3. PubMed ID: 12789487
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
[TBL] [Abstract][Full Text] [Related]
15. Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia.
Ernberg M; Lundeberg T; Kopp S
Pain; 2003 Feb; 101(3):275-282. PubMed ID: 12583870
[TBL] [Abstract][Full Text] [Related]
16. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
Stratz T; Müller W
Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
[TBL] [Abstract][Full Text] [Related]
17. [The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia].
Stratz T; Varga B; Müller W
Z Rheumatol; 2003 Feb; 62(1):42-5. PubMed ID: 12624803
[TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
19. 5-HT3 receptor antagonists: a new class of antiemetics.
Lancet; 1987 Jun; 1(8548):1470-1. PubMed ID: 2885458
[No Abstract] [Full Text] [Related]
20. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents.
Peroutka SJ
Pharmacol Rev; 1991 Dec; 43(4):579-86. PubMed ID: 1663621
[No Abstract] [Full Text] [Related]
[Next] [New Search]